Intuitive Surgical's Da Vinci 5 Momentum Can't Stop the Stock's Slide — Here's Why

Intuitive Surgical beat Q2 estimates with 19% revenue growth, but U.S. procedure growth slowed to 12% (lowest since 2021), triggering a stock sell-off amid unchanged forecasts, FDA recall, and GLP-1 drug impact.

The numbers tell a story that should have pleased the market: Intuitive Surgical shipped 468 da Vinci systems in the second quarter, including 246 of the new fifth-generation platform, while revenue jumped 19% to $2.89 billion and earnings per share surged 28% to $2.80, comfortably beating analyst estimates on both fronts. Yet the stock tumbled to a 52-week low of €299.60 on Monday and has clawed back only marginally to €315.30, a gain of 1.71% that feels more like a pause than a reversal. The disconnect is stark—and it is being driven by a single, worrisome trend that has overshadowed everything else.

Global procedure growth came in at a healthy 16% for the quarter, but the U.S. market—Intuitive's biggest—decelerated to roughly 12%, marking the slowest pace since 2021. That slowdown, combined with management's decision to leave the full-year procedure growth forecast unchanged at 13.5% to 15.5%, triggered the most severe single-day sell-off the stock has seen in years. Investors had hoped for an upward revision; instead, they got a warning that growth is likely to moderate further in the second half of the year. Since the start of 2024, the shares have lost 35.54% of their value.

The reasons behind the U.S. deceleration are both structural and regulatory. Chief Financial Officer Jamie Samath pointed to the expiration of Affordable Care Act premium subsidies, which is crimping elective procedures in the U.S. Separately, the rising popularity of GLP-1 weight-loss drugs is eating into demand for bariatric surgery, a segment that had been a meaningful growth driver. Adding to the unease, the FDA has flagged safety concerns over a component used in da Vinci staplers after reports of patient injuries. The company conducted a worldwide Class II recall of certain parts in April, leaving open questions about litigation risk and replacement costs.

Wall Street’s reaction has been a flurry of price target cuts, even as most analysts maintain a positive long-term view. Bernstein Societe Generale Group trimmed its target to $685 from $750 but raised its 2027 earnings-per-share estimate by 4% to $12.71—a rare instance of raising a forecast while lowering a target. The list of downgrades in terms of price targets is extensive: JPMorgan to $450, Wells Fargo to $487, Stifel to $550, Citigroup to $500, RBC Capital to $575, Leerink Partners to $454, TD Cowen to $485, Mizuho to $400, Baird to $500, BTIG to $469, and Evercore ISI to $375. Most retained their "overweight" or "outperform" ratings, underscoring the split between operational confidence and valuation anxiety. Piper Sandler’s Adam Maeder noted the U.S. procedure deceleration was about 200 basis points sequentially and missed Wall Street expectations, but he kept an "overweight" rating while cutting his target to $470. Leerink’s Mike Kratky described the sell-off as "increasingly overdone," while Evercore’s Vijay Kumar struck a more cautious note, arguing the U.S. weakness is the most pronounced in three years and revives broader questions about medtech demand.

Technically, the chart offers little comfort. The stock trades roughly 13% below its 50-day moving average of €358.26 and about 26% below its 200-day moving average of €418.97. The 14-day relative strength index sits at 36.6, creeping toward oversold territory, but no reversal pattern has yet formed. Annualized 30-day volatility has spiked to nearly 54%, reflecting the turbulent trading since the earnings release. From the January all-time high of €516.50, the shares are down almost 39%, a valuation correction that has been brutal and swift.

Yet for all the gloom, the operational engine remains robust. The da Vinci 5 rollout is accelerating—246 units placed in the quarter, up sharply from 180 in the same period last year—and the company raised its 2026 adjusted gross margin forecast to a range of 68.0% to 69.0%. Intuitive holds roughly $8.6 billion in cash and investments, providing firepower for continued investment in artificial intelligence and its surgical ecosystem. The trade-in cycle of older systems continues to support equipment sales.

The stock today reflects a market torn between near-term headwinds and long-term strengths. The U.S. procedure growth narrative has shifted from tailwind to headwind, and until that trajectory stabilizes—or the company delivers evidence that the slowdown is temporary—the premium valuation that Intuitive Surgical once commanded will remain under siege. The da Vinci 5 pipeline is full, but the market is watching the surgery schedule first.